Matthew Birnbaum

Matthew Birnbaum has extensive experience in market insights and analytics within the pharmaceutical and biotechnology sectors. Currently serving as Associate Director at Viridian Therapeutics, Inc. since March 2025, Matthew previously held roles as a Product Launch Specialist at Kolon TissueGene, Inc. and an Independent Consultant. Prior experience includes a Senior Associate position at Charles River Associates, where responsibilities encompassed project management, client communication, and market research. Matthew has also contributed to bioStrategies Group in various capacities, including Senior Consultant and Senior Analyst. Matthew holds a Bachelor of Science degree in Chemistry from Emory University, completed in May 2013.